Discover Briumvi Uses, Dosage, and Side Effects

NEW YORK, April 8, 2025 (GLOBE NEWSWIRE) — TG Therapeutics, Inc.(TGTX) announced today that it will publish data on BRIUMVI® (ublituximab-xiiy) for the treatment of patients with relapsing multiple sclerosis (RMS).

Michael S. Weiss, Chief Executive Officer and Chairman of TG Therapeutics stated, “The results of the retrospective ENAMOR survey, which includes data from approximately 400 individuals across 21 MS centers who have been treated with BRIUMVI in the real-world setting, showed a favorable tolerability profile, including a lower rate of infusion related reactions at the first BRIUMVI dose than was observed in the ULTIMATE Phase 3 trials….”

What Is The Drug Briumvi Used For?

Briumvi (generic name: ublituximab) is a medication used to treat multiple sclerosis (MS), specifically relapsing forms of MS.

It’s an intravenous infusion that works by targeting and depleting certain types of immune cells called B-cells, which are believed to play a role in the autoimmune processes that damage the nervous system in MS.

By reducing the activity of B-cells, it helps decrease inflammation and slows down the progression of the disease. It is typically used in people with relapsing MS who haven’t responded to or aren’t suitable for other disease-modifying therapies (DMTs).

How Does Briumvi Work?

Ublituximab is a glycoengineered chimeric IgG1 antibody that targets a specific epitope on the B-cell antigen CD20, distinct from the epitope targeted by rituximab, orolizumab, and oftamumab and promotes antibody-independent cytolysis (ADCC) of B-cells by natural killer (NK) cells.

After glycoengineering reduction in fructose concentration increases the affinity of Ublituximab for CD16A, a membrane receptor involved in NK cell activation, which increases its antibody-dependent cytolytic activity by 25-30-fold.

In addition to the retention of CD20-negative plasma cells, this targeted depletion of CD20-positive immature and mature B cells has been associated with a reduced incidence of both new-onset and progressive brain injury.

The use of Ublituximab has been associated with a reduction in the incidence of new-onset and progressive brain injury, as well as a reduction in the number of cells that have been targeted by the drug.

What Is The Difference Between Briumvi And Ocrevus?

🔍Targeted action: Both target CD20+ B-cells, but Briumvi might offer a slightly more selective mechanism.

🔍Administration: Both are IV infusions, but its loading dose is typically simpler (single dose) compared to Ocrevus.

🔍Indications: Ocrevus is approved for both relapsing and primary progressive MS, whereas it is approved only for relapsing MS.

🔍Safety and Side Effects: Similar safety profiles, with infusion reactions and infection risks.

How Do You Feel After A Briumvi Infusion?

After a Ublituximab infusion, most people can expect to feel a range of effects, and these can vary based on individual reactions. However, here are some common experiences:

Immediate Side Effects (During or Right After the Infusion):

🔍Some people may experience mild reactions like fever, chills, or nausea during or shortly after the infusion.

🔍You may also feel some dizziness or lightheadedness as your body adjusts to the medication.

🔍An infusion reaction, such as a headache or a skin rash, could also occur in some cases, though these are typically mild.

Post-Infusion (Several Hours to Days After):

🔍You might feel a bit tired or fatigued, which is fairly common after an infusion.

🔍Some might experience muscle aches or joint pain.

🔍Rarely, there might be a longer-lasting effect, but overall, the infusion doesn’t typically lead to significant or long-term side effects for most patients.

Briumvi Safety And Tolerability

Infusion-related reactions (IRRs) are the most common complication, typically occurring within 24 hours of the first dose. Symptoms are mild to moderate and tend to lessen with subsequent doses.

Serious infections (e.g., respiratory tract and herpesvirus-related) may occur due to prolonged B-cell depletion, affecting ~5% of patients in trials.

Generally well-tolerated, with no fatal side effects reported. Common mild side effects include limb pain, insomnia, and fatigue.

Rapid onset may also increase the risk of side effects. Antidrug antibodies (ADAs) are a concern; more data are needed on immunogenicity.

Briumvi (Ublituximab) is contraindicated in pregnancy and in patients with prior hepatitis B infection.

In two major studies of 1,089 patients with relapsing forms of MS, the average number of relapses per year for patients treated with Briumvi was less than half that of patients treated with teriflunomide, another MS drug (0.09 and 0.23 relapses per year, respectively).

The study also showed that patients treated with Briumvi had fewer lesions on brain scans compared to those taking teriflunomide (0.013 versus 0.38 lesions per scan), suggesting less active MS.

Briumvi Dosing Information

Briumvi for the treatment of multiple sclerosis. Usual adult dose:

First infusion	150 mg intravenously over at least 4 hours.
Second infusion (2 weeks after first infusion)	450 mg by IV over at least 1 hour
Follow-up infusion (24 weeks after the first infusion and every 24 weeks thereafter)	450 mg intravenously over at least 1 hour every 24 weeks

Common Briumvi Side Effects

The most common Briumvi medicine side effects are:

❗infusion reactions, which may include symptoms such as dizziness, nausea, light-headed, itchy, sweaty, headache, chest tightness, back pain, trouble breathing, or swelling in your face;

❗cold sores around your mouth (herpes infections), skin sores or blisters, itching, tingling, burning pain in your thigh or lower back;

❗cold symptoms such as stuffy nose, sneezing, sore throat;

❗pain in your hands and feet;

❗sleep problems (insomnia); or tiredness.

About DengYueMed – HK Drug Wholesale Distributor

As a legally compliant drug import and export company, DengYueMed is certified by the pharmacy & poisons board of Hong Kong — you can verify our qualification on their official website.

Our efforts to improve the affordability of Briumvi medicine aim to ensure that more patients can benefit from this important medication.

HK DengYue provides detailed medicine information, transparent pricing, and responsive support to ensure a smooth and reliable buying experience.

Feel free to reach out anytime to discuss your needs or ask questions about the medicine.

We welcome you to contact us for a consultation.